================================================================================
                                  UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                     Form 10-Q

(Mark One)
[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange
    Act of 1934

For the quarterly period ended September 30, 1999, or

[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities
    Exchange Act of 1934

For the transition period from _________________ to __________________

Commission file number      000-21615
                           ------------


                             BOSTON BIOMEDICA, INC.
           (Exact name of Registrant as Specified in its Charter)

     Massachusetts                                   04-2652826
------------------------                       ----------------------
    (State or other                               (I.R.S. Employer
    Jurisdiction of                               Identification No.)
      Incorporation or
     Organization)

   375 West Street,
   West Bridgewater,
     Massachusetts                                   02379-1040
------------------------                       ----------------------
 (Address of Principal                              (Zip Code)
  Executive Offices)

Registrant's telephone number, including area code    (508) 580-1900
                                                      --------------

         Indicate  by check  whether the  registrant:  (1) has filed all reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
registrant was required to file such reports),  and (2) has been subject to such
filing requirements for the past 90 days.

                                                         Yes [X]         No [ ]

     The number of shares  outstanding of the Registrant's  only class of common
stock as of November 12, 1999 was 4,773,371.

================================================================================
<PAGE>

Part I. Financial Information

Item 1. Financial Statements



                     BOSTON BIOMEDICA, INC. AND SUBSIDIARIES

                        CONSOLIDATED STATEMENTS OF INCOME

                                   (Unaudited)

<TABLE>
<CAPTION>
                                              For the Three Months Ended           For the Nine Months Ended
                                                    September 30,                        September 30,
                                            -------------------------------     --------------------------------
                                                 1999             1998              1999              1998
                                            ---------------   -------------     --------------    --------------
REVENUE:
<S>                                            <C>             <C>               <C>                <C>
   Products                                    $ 3,649,818     $ 3,037,553       $ 10,597,343       $ 9,417,716
   Services                                      3,830,124       3,143,406         10,866,421         9,419,169
                                            ---------------   -------------     --------------    --------------
         Total revenue                           7,479,942       6,180,959         21,463,764        18,836,885

COSTS AND EXPENSES:
   Cost of product sales                         1,780,760       1,575,772          5,411,944         5,022,361
   Cost of services                              2,794,385       2,157,365          7,906,037         6,479,595
   Research and development                        891,145         526,167          2,382,206         1,542,147
   Acquired research and development               -             3,380,812            -               4,230,812
   Selling and marketing                         1,021,324         913,891          3,129,141         2,768,518
   General and administrative                    1,291,832         986,202          3,503,497         2,999,214
                                            ---------------   -------------     --------------    --------------
         Total operating costs and expenses      7,779,446       9,540,209         22,332,825        23,042,647

         Loss from operations                     (299,504)     (3,359,250)          (869,061)       (4,205,762)

Interest income                                      2,941             352              3,796            27,393
Interest expense                                  (118,143)        (15,458)          (294,891)          (19,600)
                                            ---------------   -------------     --------------    --------------

         Loss before income taxes                 (414,706)     (3,374,356)        (1,160,156)       (4,197,969)

Benefit from (provision for) income taxes          157,588          (2,453)           440,860           310,520
                                            ---------------   -------------     --------------    --------------

         Net loss                               $ (257,118)   $ (3,376,809)        $ (719,296)     $ (3,887,449)
                                            ===============   =============     ==============    ==============


          Net loss per share, basic and diluted    $ (0.05)        $ (0.72)           $ (0.15)          $ (0.84)

Number of shares used to calculate net income per share
          Basic and diluted                      4,769,003       4,665,603          4,669,217         4,650,158

</TABLE>

                 See Notes to Consolidated Financial Statements

                                       2

<PAGE>


                     BOSTON BIOMEDICA, INC. AND SUBSIDIARIES

                           CONSOLIDATED BALANCE SHEETS

                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                           September 30,     December 31,
                                                                               1999             1998
                                                                           -------------   --------------

                               ASSETS
CURRENT ASSETS:
<S>                                                                        <C>              <C>
    Cash and cash equivalents                                                 $ 234,821        $ 146,978
    Accounts receivable, less allowances of $873,083 in 1999 and
       $623,710 in 1998                                                       5,594,365        6,086,693
    Inventories                                                               6,921,476        6,689,768
    Prepaid expenses and other current assets                                   804,627          479,983
    Deferred income taxes                                                       963,581          847,268
                                                                           -------------   --------------
                Total current assets                                         14,518,870       14,250,690
                                                                           -------------   --------------

Property and equipment, net                                                   7,608,764        6,925,423

OTHER ASSETS:
    Goodwill and other intangibles, net                                       2,643,752        2,809,825
    Deposits and other assets                                                    84,455           96,447
                                                                           -------------   --------------
                                                                              2,728,207        2,906,272
                                                                           -------------   --------------
              TOTAL ASSETS                                                 $ 24,855,841     $ 24,082,385
                                                                           =============   ==============


                LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:
    Accounts payable                                                        $ 2,260,571      $ 2,369,495
    Accrued compensation expenses                                             1,289,828        1,284,162
    Other accrued expenses                                                      911,640          795,642
    Current maturities of long-term debt                                         15,286           15,569
    Deferred revenue                                                             29,883          690,760
                                                                           -------------   --------------
                Total current liabilities                                     4,507,208        5,155,628
                                                                           -------------   --------------

LONG-TERM LIABILITIES:
    Long-term debt, less current maturities                                   6,169,188        3,988,602
    Other liabilities                                                           450,634          730,138
    Deferred income taxes                                                       154,965          139,363

STOCKHOLDERS' EQUITY:
    Common stock, $.01 par value; 20,000,000 shares authorized in
       1999 and 1998; 4,770,153 issued and outstanding in 1999 and
       4,667,816 in 1998                                                         47,701           46,678
    Additional paid-in capital                                               16,642,182       16,418,717
    Accumulated deficit                                                      (3,116,037)      (2,396,741)
                                                                           -------------   --------------
                Total stockholders' equity                                   13,573,846       14,068,654
                                                                           -------------   --------------
             TOTAL LIABILITIES & STOCKHOLDERS' EQUITY                      $ 24,855,841     $ 24,082,385
                                                                           =============   ==============
</TABLE>


                 See Notes to Consolidated Financial Statements

                                       3

<PAGE>



                     BOSTON BIOMEDICA, INC. AND SUBSIDIARIES

                      CONSOLIDATED STATEMENTS OF CASH FLOWS

                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                    For the Nine Months Ended
                                                                           September 30,
                                                                 -----------------------------
                                                                     1999            1998
                                                                 --------------  -------------
CASH FLOWS FROM OPERATING ACTIVITIES:
<S>                                                              <C>            <C>
    Net loss                                                        $ (719,296)  $ (3,887,449)
    Adjustments to reconcile net loss to net
       cash (used in) provided by operating activities:
    Depreciation and amortization                                    1,126,511        909,905
    Provision for doubtful accounts                                    171,103        197,903
    Other liabilities                                                 (279,504)       123,578
    Deferred income taxes                                             (100,711)       (56,342)
    Acquired research and development                                        -      4,230,812
Changes in operating assets and liabilities:
    Accounts receivable                                                321,225        756,695
    Inventories                                                       (231,708)    (1,068,408)
    Prepaid expenses and other current assets                         (324,644)      (268,266)
    Accounts payable                                                  (108,924)       112,289
    Accrued compensation and other expenses                            121,664       (183,971)
    Deferred revenue                                                  (660,877)      (447,189)
                                                                 --------------  -------------
        Net cash (used in) provided by operating activities           (685,161)       419,557
                                                                 --------------  -------------

CASH FLOWS FOR INVESTING ACTIVITIES:
    Acquired research and development                                        -       (850,000)
    Payments for additions to property and equipment                (1,643,779)    (2,139,695)
    Change in deposits and other assets                                 11,992         19,522
    Acquisitions (net of cash acquired)                                      -       (878,901)
                                                                 --------------  -------------
        Net cash used in investing activities                       (1,631,787)    (3,849,074)
                                                                 --------------  -------------

CASH FLOWS FROM FINANCING ACTIVITIES:
    Proceeds from long term debt                                     2,191,836        883,598
    Repayments of long-term debt                                       (11,533)             -
    Proceeds from common stock issued                                  224,488         89,149
                                                                 --------------  -------------
        Net cash provided by financing activities                    2,404,791        972,747
                                                                 --------------  -------------

INCREASE (DECREASE) IN CASH:                                            87,843     (2,456,770)
    Cash and cash equivalents, beginning of period                     146,978      2,772,360
                                                                 --------------  -------------
    Cash and cash equivalents, end of period                        $  234,821   $    315,590
                                                                 ==============  =============
</TABLE>

                 See Notes to Consolidated Financial Statements

                                       4
<PAGE>
                     BOSTON BIOMEDICA, INC. AND SUBSIDIARIES

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(1)  Basis of Presentation

     The  accompanying  unaudited  consolidated  financial  statements have been
prepared in accordance  with generally  accepted  accounting  principles for the
interim financial information and with the instructions to Form 10-Q and Article
10 of Regulation  S-X.  Accordingly,  they do not include all of the information
and footnotes required by generally accepted accounting  principles for complete
financial statements. In the opinion of management,  all adjustments (consisting
of  only  normal  recurring   adjustments)   considered  necessary  for  a  fair
presentation have been included. Operating results for the three and nine months
ended September 30, 1999 are not necessarily  indicative of the results that may
be expected  for the year ending  December 31,  1999.  For further  information,
refer to the consolidated financial statements and footnotes thereto included in
the Annual  Report on Form 10-K for the fiscal year ended  December 31, 1998 for
Boston Biomedica,  Inc. and Subsidiaries ("the Company" or "Boston  Biomedica").
Certain prior year amounts in the  consolidated  financial  statements  may have
been reclassified to conform to the current year's presentation.

(2)  Use of Estimates

     In conformity with generally accepted accounting principles,  management is
required to make estimates and assumptions  that affect the reported  amounts of
assets,  liabilities,  revenues,  and expenses for the periods  presented.  Such
estimates include reserves for uncollectable  accounts receivable as well as the
net  realizable  value of  inventories.  Actual  results  could  differ from the
estimates and assumptions used by management.

(3)  Inventories

    Inventories consist of the following:

                                        September 30,      December 31,
                                             1999              1998
                                        ---------------   ----------------
Raw materials                              $ 2,568,441        $ 2,407,154
Work-in-process                              1,849,841          1,788,399
Finished goods                               2,503,194          2,494,215
                                        ---------------   ----------------
                                           $ 6,921,476        $ 6,689,768
                                        ===============   ================

(4)  Segment Reporting and Related Information (all dollar amounts in thousands)

     Selected  summarized  results for the Company's four operating segments are
as follows:

<TABLE>
<CAPTION>
                               Three Months Ended Sept. 30,    Nine Months Ended Sept. 30,
Segment revenue:                   1999           1998            1999            1998
                               -------------   ------------   -------------   -------------
<S>                             <C>            <C>            <C>             <C>
Diagnostics                         $ 4,465        $ 3,926        $ 12,407        $ 11,782
Clinical Laboratory Services          2,677          1,817           7,346           5,129
Laboratory Instrumentation              611            908           2,537           3,113
Other                                    80              -             163               -
Eliminations                           (353)          (470)           (989)         (1,187)
                               -------------   ------------   -------------   -------------
   Total revenue                    $ 7,480        $ 6,181        $ 21,464        $ 18,837
                               =============   ============   =============   =============
</TABLE>

<TABLE>
<CAPTION>
                                  Three Months Ended Sept. 30,    Nine Months Ended Sept. 30,
Segment operating income (loss):      1999           1998            1999            1998
                                  -------------   ------------   -------------   -------------
<S>                               <C>            <C>             <C>             <C>
Diagnostics                              $ 255          $ 219           $ 515           $ 477
Clinical Laboratory Services               189            (22)            469              83
Laboratory Instrumentation                (333)          (149)           (682)           (447)
Other                                     (411)           (26)         (1,171)            (88)
Acquired R&D                                 -         (3,381)              -          (4,231)
                                  -------------   ------------   -------------   -------------
   Total loss from operations           $ (300)      $ (3,359)         $ (869)       $ (4,206)
                                  =============   ============   =============   =============
</TABLE>
                                        5

<PAGE>
                     BOSTON BIOMEDICA, INC. AND SUBSIDIARIES

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(4)  Segment Reporting and Related Information (Continued)

                                               Sept. 30,        Dec. 31,
Identifiable segment assets:                      1999           1998
                                              -------------   ------------

Diagnostics                                       $ 16,747       $ 16,548
Clinical Laboratory Services                         3,141          2,348
Laboratory Instrumentation                           3,992          4,428
Other                                                  976            758
                                              =============   ============
   Total assets                                   $ 24,856       $ 24,082
                                              =============   ============

(5)  Acquired Research and Development

     In March 1998, the Company  acquired from BioSeq,  Inc.("BioSeq")  the sole
and exclusive worldwide right to development stage technology, including the use
of BioSeq technical information, licensed processes and improvements to develop,
manufacture,  market and sell or sublicense products or services in the field of
human in vitro  immunodiagnostics.  In accordance with accounting  standards for
purchased  research and  development,  costs totaling  $850,000 were expensed in
that period.

     On  September  30, 1998 the Company  acquired  the  remaining  common stock
outstanding  of BioSeq  (approximately  81%).  The Company's  aggregate  cost of
acquiring  all  of  BioSeq's  equity  was  approximately  $4,226,000,  of  which
approximately $3,380,000 was expensed as in-process research and development.

(6)  Computation of Net Loss per Share

     Net loss per share is computed using average common stock  outstanding  for
the periods  presented.  Potentially  dilutive  securities of 79,165 and 203,396
were not included in the computation of diluted  earnings per share for the nine
months ended and 145,037 and 136,554 for the three months  ended  September  30,
1999 and 1998,  respectively.  These  potentially  dilutive  securities  are not
included  because to do so would have been  antidilutive as the Company was in a
loss position for all periods presented.

(7)  The Amended Line of Credit Agreement

     Effective June 30, 1999, the Company entered into an amended revolving line
of credit agreement (the "Amended Line") with its bank,  increasing the facility
to $10 million from $7.5 million.  The Amended Line matures June 30, 2001; bears
interest  at the  Company's  option  based on either  the base rate plus 1/4% or
LIBOR plus 2.75%;  carries a facility fee of 1/4% per annum,  payable quarterly;
and  is  collateralized  by  substantially  all of the  assets  (excluding  real
property)  of the  Company.  Borrowings  under the  Amended  Line are limited to
commercially   standard  percentages  of  accounts  receivable,   inventory  and
equipment.  The Company had approximately  $863,000  available under the Amended
Line as of September 30, 1999.

     The  Amended  Line  contains   covenants   regarding  the  Company's  total
liabilities to tangible net worth ratio,  minimum debt service  coverage  ratio,
and maximum net loss. The Amended Line further  provides for restrictions on the
payment  of  dividends,  incurring  additional  debt,  and the amount of capital
expenditures.

(8)  Changes in Securities and Use of Proceeds

     On August 18, 1999, the Company sold warrants to purchase 500,000 shares of
the Company's common stock to Paradigm Group,  L.L.C.,  an accredited  investor,
for an aggregate purchase price of $50,000. The warrant purchase was recorded as
additional paid-in capital.  Warrants to purchase 400,000 shares are exercisable
at $4.25 per share and warrants to purchase  100,000  shares are  exercisable at
$5.25 per share, and the warrants expire in February 2000.  Warrants to purchase
a total of 75,000 shares of the Company's common stock,  expiring in August 2001
and with exercise prices ranging from $4.25 to $8.00 per share, were also issued
to National Securities, a registered broker-dealer.

                                       6

<PAGE>
                     BOSTON BIOMEDICA, INC. AND SUBSIDIARIES

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(9)  Income Taxes

     In  accordance  with SFAS 109,  Accounting  for Income  Taxes,  The Company
records assets and  liabilities to reflect future  deductible and taxable items.
On  September  30,  1999 the  Company's  deferred  tax asset,  net of  valuation
allowances   and  deferred  tax   liabilities,   was   approximately   $809,000.
Approximately  $324,000  relates to the  allowance  for  doubtful  accounts  and
$306,000 relates to a temporary difference created by the March 1998 Acquisition
of  technology  from BioSeq.  The Company  feels that it is more likely than not
that the tax asset,  as reflected on the  September 30, 1999 balance  sheet,  is
realizable and therefore no valuation allowance is required at this time.


                                       7

<PAGE>
Item 2.  Management's  Discussion  and  Analysis  of Results of  Operations  and
         Financial Condition.

Three Months Ended September 30, 1999 and 1998

     Total revenue  increased  21.0% or  $1,299,000 to $7,480,000  for the three
months ended September 30, 1999 from  $6,181,000 in the prior year period.  This
increase was the result of an increase in product  sales of 20.2%,  or $612,000,
to  $3,650,000  and an increase in specialty  laboratory  services of 21.8%,  or
$687,000,  to  $3,830,000.  The  increase  in product  revenue was the result of
strong  sales of OEM panels  within  the  Quality  Control  product  group,  and
stronger diagnostic component sales. The growth in these two groups was tempered
somewhat by flat  Accurun (R) sales as some new  products  were  delayed to meet
customer OEM  requirements.  The  increase in service  revenue was the result of
continued  strong  clinical  laboratory  testing  sales from both  nucleic  acid
(molecular)  testing  for HIV,  Hepatitis  C, and Lyme  Disease  and  immunology
testing.

     Gross profit  increased  18.7%, or $457,000,  to $2,905,000 for the current
three  months from  $2,448,000  in the prior year period.  Overall  gross margin
decreased  to 38.8% from 39.6%.  The  decrease  was  primarily  attributable  to
services.  The gross margin on services  decreased  to 27.0% from 31.4%,  as the
Company  used an  aggressive  pricing  strategy  to  capture  a  portion  of its
increased  clinical  laboratory  testing  revenue.  This  decrease was partially
offset by an improved  product  gross profit  margin of 51.2%  compared to 48.1%
from the prior period,  as the  increased  product sales were achieved at normal
profit margins.

     Research and development expenses increased 69.4%, or $365,000, to $891,000
for the  current  three  months  from  $526,000  in the prior year  period.  The
increase is primarily the result of increased spending on development efforts in
pressure  cycling  technology  ("PCT").  Also  contributing  to the increase was
continued spending on new molecular tests and Quality Control Products.

     There  was an  accounting  charge  of  $3,381,000  for  the  quarter  ended
September 30, 1998 related to in-process technology as a result of the Company's
$4,266,000 acquisition of BioSeq and PCT.

     Selling and marketing expenses increased 11.8%, or $107,000,  to $1,021,000
for the current  three  months  from  $914,000  in the prior year  period.  This
increase was primarily the result of increased  spending in the areas of product
promotion,  and incentive  compensation  expense at both BBI Diagnostics and BBI
Clinical Laboratories.

     General and  administrative  expenses  increased  31.0%,  or  $306,000,  to
$1,292,000  for the current three months from $986,000 in the prior year period.
The increase was a result of several  factors:  effective August 1, 1999 certain
personnel costs reclassified to G&A from other expense categories as a result of
the Company's  reorganization;  higher  allowances  recorded on clinical testing
receivables;  increased  professional fees related to the legal  organization of
the drug discovery  program;  and increased  business  development  and investor
relations activities.

     Net  interest  expense was  $115,000  for the current  quarter  compared to
$15,000 in the prior year period due to an increase in long-term  debt under the
line of credit agreement.

     The Company  recorded a tax benefit in both quarters  based on the combined
federal and state statutory rate of 38%.

Nine Months Ended September 30, 1999 and 1998

     Total revenue  increased 13.9%, or $2,627,000,  to $21,464,000 for the nine
months ended September 30, 1999 from $18,837,000 in the prior year period.  This
increase was the result of an increase in product sales of 12.5%, or $1,180,000,
to $10,597,000  and an increase in specialty  laboratory  services of 15.4%,  or
$1,447,000, to $10,866,000.  The increase in product revenue is due to continued
strong Accurun(R) sales as well as significant increases in diagnostic component
and laboratory  instrument sales. The increase in specialty  laboratory services
is  primarily  attributable  to  increases  in clinical  laboratory  testing and
repository  services  under  the  new  NHLBI  (National  Heart  Lung  and  Blood
Institute)  contract,  partially  offset by a decline in  laboratory  instrument
services as the contract  with ABX,  Inc. was  completed in the first quarter of
1999.

                                       8

<PAGE>


     Gross profit  increased  11.1%, or $811,000,  to $8,146,000 for the current
nine months from  $7,335,000  in the prior year period.  The gross profit margin
decreased  to 38.0% for the current  nine months  versus 38.9% in the prior year
period.  This decrease is due primarily to lower margins on clinical  laboratory
testing services and repository  activities,  partially offset by higher product
margins.

    Research  and  development   expenses  increased  54.5%,  or  $840,000,   to
$2,382,000 for the current nine months from $1,542,000 in the prior year period.
The increase is primarily the result of development  efforts in PCT and the drug
development  program as well as additional  spending on new molecular  tests and
Quality Control Products.

    There were two accounting charges during the nine months ended September 30,
1998. In the first quarter there was an accounting charge of $850,000 related to
the acquisition of the worldwide  exclusive rights to BioSeq's  immunodiagnostic
research and  development  technology.  In the third quarter,  the Company had a
charge of $3,381,000 related to in-process  research and development as a result
of the Company's $4,266,000 acquisition of BioSeq.

     Selling and marketing expenses increased 13.0%, or $361,000,  to $3,129,000
for the current  nine  months  from  $2,768,000  in the prior year  period.  The
increase  was  attributable  primarily  to  increased  promotion  and  incentive
compensation expenditures.

     General and  administrative  expenses  increased  16.8%,  or  $504,000,  to
$3,503,000 for the current nine months from $2,999,000 in the prior year period.
The increase was a result of several  factors:  effective August 1, 1999 certain
personnel  costs were  reclassified  from other  expense  categories to G&A as a
result of the Company's  reorganization;  higher allowances recorded on clinical
testing   receivables;   increased   professional   fees  related  to  both  the
reorganization and of the legal organization of the drug discovery program;  and
increased business development and investor relations activities.

     Net  interest  expense of $291,000  was  incurred in 1999 versus  income of
$8,000 for the prior year period as the  Company  began  incurring  debt in July
1998.

     The Company  recorded a tax benefit in both quarters  based on the combined
federal and state statutory rate of 38%.

Liquidity and Financial Condition

     At  September  30,  1999,  the  Company  had cash and cash  equivalents  of
approximately  $235,000  and  working  capital of  $10,012,000.  Trade  accounts
receivable  decreased  $321,000 from the prior year end balance as compared to a
decrease of $757,000 for the same period last year. Inventory increased $232,000
primarily  due to a higher  level of  Basematrix  and OEM  panel  orders  at BBI
Diagnostics.  However,  this  represents a less  significant  increase  than the
$1,068,000  increase  realized  last  year,  as  the  Company  has  focused  its
purchasing on more immediate production needs.

     The Company has  financed  its  operations  to date  through cash flow from
operations, borrowings from its bank and the sale of its common stock. Effective
June 30, 1999,  the Company  expanded its revolving line of credit with its bank
to $10 million from $7.5  million.  The Company  expects its cash flow,  working
capital,  and  available  borrowings  under its  Amended  Line to meet  existing
operational and capital needs for at least the next twelve months.


     Net cash used in  operations  for the nine months ended  September 30, 1999
was $685,000 as compared to cash provided by operations of $420,000 in the prior
year  period.  This  decrease  in cash flow was  primarily  attributable  to the
Company's  step-up  in  research  and  development  expenditures  in 1999  and a
decrease in the rate of trade receivable collections compared to the prior year.

     Cash used in investing  activities for the nine months ended  September 30,
1999 was  $1,632,000  compared to $3,849,000 in the prior year period.  The cash
used in 1999 relates to expenditures for manufacturing, laboratory

                                       9

<PAGE>

and information  technology  equipment as well as continued  improvements at the
Company's  Massachusetts and Maryland facilities.  This represents a slower rate
of spending than in 1998 as several capital projects are nearing completion. The
1998 amount also includes  $850,000 for acquired  research and development,  and
$879,000 of net cash outflow  related to the BioSeq  acquisition.  (See Footnote
5).

     Cash provided by financing  activities for the nine months ended  September
30, 1999 was  $2,405,000  compared to  $973,000  in the prior year  period.  The
increase  was  primarily  related  to the  increased  debt  from  the  Company's
revolving line of credit  incurred to finance  operating and additional  working
capital needs, as well as new property and equipment purchases.

     The Company anticipates significant capital expenditures to continue during
the  remainder  of 1999  and 2000 as it plans  to  complete  renovations  to its
manufacturing  facility  in  Massachusetts  and a  new  repository  facility  in
Frederick Maryland,  as well as implement a fully integrated Enterprise Resource
Planning  System  ("ERP")  at all  locations.  Except  for  purchase  orders  in
connection with the manufacturing expansion, the Frederick facility, and the ERP
System, there were no material financial commitments for capital expenditures as
of September 30, 1999.

Year 2000 Readiness Disclosure

     The  following  disclosure  is a Year  2000  ("Y2K")  readiness  disclosure
statement pursuant to the Year 2000 Readiness and Disclosure Act.

     Boston   Biomedica's   Year  2000  program  is  designed  to  minimize  the
possibility  of serious Year 2000  interruption.  Possible  Year 2000 worst case
scenarios  include  the  interruption  of  significant  parts  of the  Company's
business as a result of internal  business  system failure or the failure of the
business  systems  of  its  suppliers,   distributors  or  customers.  Any  such
interruption  may have a material  adverse  impact on the future  results of the
Company.

     In 1997 the Company decided to significantly upgrade its "business systems"
(all  computer  hardware and software used to run its  businesses  including its
operations  management,  administration and financial  systems).  Specifications
were developed for desired capabilities, including Year 2000 compliance. In 1998
the Company began assessing its Year 2000 exposure and commenced  implementation
of a plan to  achieve  Year 2000  readiness.  Based on its  review to date,  the
Company believes that its products are Year 2000 compliant.

     During the third quarter of 1998, after investigating several alternatives,
implementation  of an ERP system was started at two of the Company's four sites.
The vendor has certified that the system is Year 2000 compliant.  In April 1999,
business systems at the other two sites were upgraded to Y2K compliant  versions
of their existing software at a combined cost of approximately $5,000.

     A task force with  participants  and a site leader at each Company location
has reviewed all other  infrastructure areas including  communications  systems,
building security systems, and embedded technologies in areas such as laboratory
instruments and manufacturing  equipment. All infrastructure was found to be Y2K
compliant  with only minor  deficiencies,  which were  upgraded to Y2K compliant
equipment  and  software  versions.  The Company has surveyed  major  suppliers,
distributors,  and customers to determine the status and schedule for their Year
2000 compliance.  To date, no significant  issues have been identified,  and the
Company  expects to complete its  assessment  before year end. Where it believes
that a particular  supplier's  situation poses  unacceptable  risks, the Company
plans to identify an alternative source.

     The  costs  of  the   readiness   program  for  business   systems,   other
infrastructure  areas,  and suppliers  and  distributors  are a  combination  of
incremental external spending and use of existing internal resources.  In total,
the Company expects to spend less than $150,000 to achieve  readiness,  of which
approximately  95% has been expended to date.  This amount is based on the costs
to upgrade the existing business systems to Y2K compliant versions, and excludes
the costs of implementing the ERP system which is being  implemented for reasons
beyond Y2K compliance.

     Milestones  and  implementation  dates  and the  costs of BBI's  Year  2000
readiness  program are  subject to change  based on new  circumstances  that may
arise or new  information  becoming  available  that may change  the  underlying
assumptions or requirements.


                                       10

<PAGE>
Forward-Looking Statements

     This  Quarterly  Report on Form 10-Q  contains  forward-looking  statements
concerning the Company's  financial  performance  and business  operations.  The
Company  wishes to caution  readers of this  Quarterly  Report on Form 10-Q that
actual   results   might  differ   materially   from  those   projected  in  any
forward-looking statements.

     Factors  that could cause  actual  results to differ  from those  projected
include the possibility that due to unforeseen management, financial, technical,
and other difficulties,  reorganization of the Company's corporate structure and
management,  as  discussed in its July 22, 1999 Press  Release,  may not lead to
increased  profitability or R&D program acceleration.  Also, the Company may not
be able to develop its  research  and  development  programs  into  commercially
successful  products,  or  such  development  may  take  longer  than  currently
expected. Certain of these and other factors which might cause actual results to
differ  materially  from  those  projected  are more  fully set forth  under the
caption "Risk Factors" in the Company's  Annual Report on Form 10-K for the year
ended December 31, 1998.


                                       11
<PAGE>

    BOSTON BIOMEDICA, INC.

Part II. Other Information

Item 1. Legal Procedures

     Not Applicable.

Item 2. Changes in Securities and Use of Proceeds.

     On August 18, 1999, the Company sold warrants to purchase 500,000 shares of
the Company's common stock to Paradigm Group,  L.L.C.,  an accredited  investor,
for an aggregate purchase price of $50,000. The warrant purchase was recorded as
additional paid-in capital.  Warrants to purchase 400,000 shares are exercisable
at $4.25 per share and warrants to purchase  100,000  shares are  exercisable at
$5.25 per share, and the warrants expire in February 2000.  Warrants to purchase
a total of 75,000 shares of the Company's common stock,  expiring in August 2001
and with exercise prices ranging from $4.25 to $8.00 per share, were also issued
to National Securities, a registered broker-dealer.

Item 3. Defaults Upon Senior Securities

     Not Applicable.

Item 4. Submission of Matters to a Vote of Security Holders.

The Company held its Special  Meeting in Lieu of Annual Meeting of  Stockholders
on July 22, 1999 (the "Meeting").  A total of 4,015,460  shares,  or 84%, of the
Common Stock issued and outstanding as of the record date,  were  represented at
the meeting in person or by proxy.  At the meeting,  four  proposals  were acted
upon. The results of the elections were as follows:

1.   Richard  Schumacher  and Kevin  Quinlan were elected Class III Directors of
     the  Company,  to serve as such  until  the Year  2002  Annual  Meeting  of
     Stockholders  and  until  their  successors  have  been  duly  elected  and
     qualified,  with a minimum of  3,725,958  shares  voting in favor,  289,502
     votes withheld.

2.   The Boston  Biomedica,  Inc.  Employee  Stock  Option  Plan was  amended to
     increase  the  number  of shares  of  common  stock  which may be issued to
     2,000,000,  with 2,504,106  shares voting in favor,  330,447  against,  and
     1,180,907 shares abstaining or not voting.

3.   The Boston Biomedica, Inc. 1999 Nonqualified Stock Option Plan was adopted,
     with  2,495,189  shares  voting in favor,  331,864  against,  and 1,188,407
     shares abstaining or not voting.

4.   The Boston  Biomedica,  Inc. 1999 Employee Stock Purchase Plan was adopted,
     with  2,656,211  shares  voting in favor,  178,842  against,  and 1,180,407
     shares abstaining or not voting.

The terms of office of Directors Francis E. Capitanio,  William R. Prather,  and
Calvin A. Saravis, continued after the Meeting.

Item 5. Other Information

     Not Applicable.


                                       12
<PAGE>

Item 6.   Exhibits and Reports on Form 8-K

    (a) Exhibits

       Exhibit No.
       -----------

     3.1  Amended and Restated Articles of Organization of the Company**

     3.2  Amended and Restated Bylaws of the Company**

     4.1  Specimen Certificate for Shares of the Company's Common Stock**

     4.2  Description  of Capital Stock  (contained in the Restated  Articles of
          Organization of the Company filed as Exhibit 3.1)**

     4.3  Form of warrants issued in connection with warrant purchase  agreement
          with Paradigm Group

     10.1 Line of Credit agreement with BankBoston dated June 30, 1999

     10.2 Agreement  with  Paradigm  Group for the  purchase of  warrants  dated
          August 18, 1999

     27   Financial Data Schedule

------------------------

**   In accordance  with Rule 12b-32 under the Securities  Exchange Act of 1934,
     as amended,  reference is made to the documents  previously  filed with the
     Securities and Exchange Commission, which documents are hereby incorporated
     by reference.

     (b) Reports on Form 8-K

     None


                                       13
<PAGE>

                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  Report  to be  signed  on its  behalf by the
undersigned, thereunto duly authorized.

                                             BOSTON BIOMEDICA, INC.

Date: November 15, 1999                      By /S/ Kevin W. Quinlan
      -----------------                        ------------------------
                                               Kevin W. Quinlan, President


                                       14
<PAGE>
                             BOSTON BIOMEDICA, INC.

                                  EXHIBIT INDEX

EXHIBIT INDEX
-------------
<TABLE>
<CAPTION>
       Exhibit No.                                                                                      Reference
       -----------                                                                                      ---------

<S>    <C>       <C>                                                                                 <C>
       3.1        Amended and Restated Articles of Organization of the Company                             A**

       3.2        Amended and Restated Bylaws of the Company                                               A**

       4.1        Specimen Certificate for Shares of the Company's Common Stock                            A**

       4.2        Description of Capital Stock (contained in the Restated Articles of                      A**
                  Organization of the Company filed as Exhibit 3.1)

       4.3        Form of warrants issued in connection with warrant purchase agreement with         Filed herewith
                  Paradigm Group

       10.1       Line of Credit agreement with BankBoston dated June 30, 1999                       Filed herewith

       10.2       Agreement with Paradigm Group for the purchase of warrants dated August 18, 1999   Filed herewith

       27         Financial Data Schedule                                                            Filed herewith
</TABLE>

------------------------

A    Incorporated by reference to the Company's  Registration  Statement on Form
     S-1 (Registration No. 333-10759)(the  "Registration Statement"). The number
     set  forth  herein  is the  number  of the  Exhibit  in  said  registration
     statement.

**   In accordance  with Rule 12b-32 under the Securities  Exchange Act of 1934,
     as amended,  reference is made to the documents  previously  filed with the
     Securities and Exchange Commission, which documents are hereby incorporated
     by reference.




                                       15